Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc (NASDAQ:MRNA) shares are trading higher by 1.3% at $237.50 on continued strength after the company on Tuesday announced data showing its COVID-19 vaccine produced neutralizing titers against multiple COVID-19 variants. Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018.

Why Moderna Shares Are Moving Today

Moderna's (MRNA) share price reaches all-time high, following authorization from the government of India for mRNA-1273 and encouraging neutralizing activity against several COVID-19 variants demonstrated in studies.

Moderna (MRNA) COVID-19 Vaccine Effective Against Delta Variant

Shares of Moderna Inc. were up 2.3% in premarket trading on Wednesday, the day after the company's stock price hit an all-time high of $234.60 when the market closed on Tuesday. Moderna has one authorized product, its two-dose, mRNA-based COVID-19 vaccine; the global success of its shot, along with BioNTech and Pfizer Inc.'s COVID-19 vaccine, has opened the door for broader interest in mRNA technology.

Moderna's stock hits record price on Tuesday

BioNTech SE

A recent study undermines one key assumption underpinning the stocks' recent gains.

3 Reasons Shareholders of Moderna and BioNTech May Be In for a Shock

But it remains to be seen if his view is correct.

11 Words From Moderna's President That Could Mean Billions of Dollars in Additional Sales

Micron Technology

Starbucks

Bed Bath & Beyond

Micron, Moderna, Starbucks and Bed Bath & Beyond were our top stock trades for Wednesday. Let's look at what the charts are trying to say.

4 Top Stock Trades for Wednesday: MU, MRNA, BBBY, SBUX

Promising clinical trial results are prompting more governments to authorize the biotech's coronavirus vaccine.

Here's Why Moderna Stock Hit an All-Time High Today

Moderna, Inc.'s (NASDAQ: MRNA) COVID-19 vaccine should soon find its way into India, one of the countries worst affected by the second wave of the pandemic. What Happened: India's drug regulator, the Drugs Controller General of India, has approved the importation of Moderna's COVID-19 vaccine for restricted emergency use in India, the Hindustan Times reported, citing sources.

Moderna COVID-19 Vaccine Authorized For Emergency Use In India: What You Need To Know

Shares of Moderna Inc. gained 6.3% in trading on Tuesday after the company said its COVID-19 vaccine has been authorized for adults in India. Moderna's shot has already been authorized in more than 50 countries, including the U.S. Moderna's stock is up 118.5% this year, while the broader S&P 500 has gained 14.2%.

Moderna's stock gains as it announces authorization for its COVID-19 shot in India

Moderna Inc (NASDAQ:MRNA) said that its COVID-19 vaccine worked on various strains of the virus, including the Beta, Delta and Eta and other two first identified in Uganda and Angola. The pharma group analysed samples of blood of people who had received both doses of the jab.

Moderna says COVID-19 vaccine works on Delta variant

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces Emergency Use Authorization for its COVID-19 vaccine granted by Government of India.

Moderna Announces Emergency Use Authorization for its COVID-19 Vaccine Granted by Government of India

Moderna's results, while promising, may not reflect how the vaccines actually perform in real world scenarios against the delta and other Covid variants.

Moderna says Covid vaccine shows promise in a lab setting against variants, including delta

Shares of Moderna Inc. gained 3.1% in trading on Tuesday after the company said an in-vitro study analyzing the sera of people who have received its COVID-19 vaccine had neutralizing antibody titers that protect against infection with several variants, including the worrisome Delta variant. The Delta variant, or B.1.617.2, was first identified in India.

In-vitro study says Moderna's COVID-19 vaccine can protect against variants

Moderna said in a statement on Tuesday that it believes its COVID-19 vaccine "should remain protective against newly detected variants."

Moderna says its COVID-19 vaccine should work against the Delta variant

Pfizer

The "full" approval of Pfizer and Moderna's COVID-19 vaccines sometime this year could boost sagging vaccination rates in the U.S., though the Food and Drug Administration's decision may not happen until the end of the year.

Full FDA approval of Pfizer's and Moderna's COVID-19 shots would reinvigorate the U.S. vaccination push — but it could still be months away

COVID-19 vaccine company Moderna, Inc. (NASDAQ: MRNA) announced Monday a new hire to enhance its brand appeal. What Happened: Moderna said Kate Cronin will join the company as chief brand officer, effective July 12.

Moderna Hires Ogilvy Health CEO Kate Cronin As Chief Brand Officer To Build On COVID-19 Vaccine Momentum

The FDA on Friday added a warning to patient and provider fact sheets for the Pfizer Inc (NYSE:PFE) and Moderna Inc (NASDAQ:MRNA) COVID-19 vaccines to indicate a rare risk of heart inflammation. The fact sheets were revised for each vaccine to warn about myocarditis and pericarditis after the second dose and with the onset of symptoms within a few days after receiving the shot.

FDA Revises Pfizer, Moderna COVID-19 Vaccine Sheets With Rare Heart Inflammation Warning

Shares of Moderna Inc. gained 0.6% in trading on Monday after the company said it hired Kate Cronin, former global CEO of Ogilvy Health, as its first chief brand officer. Moderna has one authorized product in the U.S., its COVID-19 vaccine.

Moderna hires chief brand officer

Scientists found that, even four months after the first dose, the body continues to train new immune cells to protect against Covid-19, which suggests robust protection.

Pfizer And Moderna Vaccines May Offer Years-Long Protection Against Covid-19, Scientists Say

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Kate Cronin to join Moderna as Chief Brand Officer on July 12.

Kate Cronin to Join Moderna as Chief Brand Officer on July 12

The FDA mentions cases of heart inflammation in young people.

Could a Vaccine Warning Label Hurt Moderna and Pfizer?

For each Covid-19 vaccine, the fact sheets were revised to include a warning about myocarditis and pericarditis after the second dose

FDA adds warning about risk of rare heart inflammation to Pfizer, Moderna Covid vaccines

It's already a stunning success, and it's just getting started.

This Provocative Biotech Stock Is a Better Bet Than Ethereum or Dogecoin

Novavax

The biotech stocks jumped for different reasons.

Why COVID Vaccine Stocks Moderna, Novavax, and BioNTech Soared This Week

Investors are breathing easier after the FDA's response to a potential link between Moderna's vaccine and heart inflammation issues.

News for Moderna Stock (MRNA)